SCHEDULE 13G: German Investor Dr. Andreas Kluge and Gnosis Verwaltungsgesellschaft Disclose 6.78% Stake in Telix Pharmaceuticals
Beneficial Ownership Report
Dr. Andreas Kluge and Gnosis Verwaltungsgesellschaft m.b.H. have jointly reported a beneficial ownership of 6.78% in Telix Pharmaceuticals Ltd, totaling 22,675,000 ordinary shares, as of November 12, 2024.
Summary
- Dr. Andreas Kluge and Gnosis Verwaltungsgesellschaft m.b.H. (the "Reporting Persons") have filed a Schedule 13G, disclosing their beneficial ownership in Telix Pharmaceuticals Ltd.
- As of November 12, 2024, the Reporting Persons collectively beneficially own 22,675,000 ordinary shares of Telix Pharmaceuticals Ltd.
- This ownership represents 6.78% of the company's ordinary shares outstanding.
- The percentage is calculated based on 334,683,357 ordinary shares outstanding as of September 30, 2024, as reported in Telix's Form 20-F filed on October 17, 2024.
- Dr. Andreas Kluge, a German citizen, is the Managing Director of Gnosis Verwaltungsgesellschaft m.b.H., a German-organized entity, and holds shared voting and dispositive power over all 22,675,000 shares.
Sentiment
Score: 5
Explanation: A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects. It is a neutral regulatory report.
Future Outlook
NA
Industry Context
This filing indicates a significant passive investment in a pharmaceutical company by a German individual and entity. It does not provide broader industry trends or competitive analysis.
Related Party Transactions
- Dr. Andreas Kluge, as the Managing Director of Gnosis Verwaltungsgesellschaft m.b.H., has shared voting and dispositive power over the 22,675,000 ordinary shares held by Gnosis, indicating a direct relationship between the two reporting entities in their beneficial ownership of Telix Pharmaceuticals Ltd.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant passive ownership stake by Dr. Andreas Kluge and Gnosis Verwaltungsgesellschaft m.b.H., which can influence perceptions of institutional interest and stability.
Key Dates
| Date | Description |
|---|---|
| 2024-09-30 | Date of ordinary shares outstanding calculation (334,683,357 shares) as reported in Telix's Form 20-F. |
| 2024-10-17 | Date Telix Pharmaceuticals Ltd filed its Form 20-F with the SEC, reporting shares outstanding. |
| 2024-11-12 | Date of event which requires the filing of this Schedule 13G, representing the beneficial ownership snapshot. |
| 2025-02-14 | Date the Schedule 13G was signed and filed by Dr. Andreas Kluge on behalf of himself and Gnosis Verwaltungsgesellschaft m.b.H. |
Keywords
Telix Pharmaceuticals Ltd, Schedule 13G, Beneficial Ownership, Andreas Kluge, Gnosis Verwaltungsgesellschaft m.b.H., Ordinary Shares, SEC Filing, Shareholding, Investment, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.